Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Union Pacific Corporation (UNP) vs Viatris Inc (VTRS) Price & Performance

Union Pacific CorporationTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Union Pacific Corporation vs Viatris Inc — how do they compare? Union Pacific Corporation trades at $278.34 (market cap $165.27B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Union Pacific Corporation is far larger — about 8.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Union Pacific Corporation for 105 Days and Viatris Inc for 57 Days on average.

UNPVTRS
Market Cap
$165.27B$20.03B
Volume
1,474,11714,109,977
Sector
IndustrialsHealth
52-Week High
$310.62$18.27
52-Week Low
$216.37$9.74
Typical Hold Time
105 Days57 Days
Enterprise Value
$194.33B$32.15B
Dividend Yield
2.04%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Union Pacific Corporation

Union Pacific (UNP) trades at $278.20, up 1.28% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company maintains robust profitability with a 28.85% net margin and 39.7% ROE. Positive sentiment is driven by volume growth, a pending Norfolk Southern merger, and dividend reliability, though merger uncertainty and fuel costs pose risks.

Outlook is positive given earnings momentum and strategic initiatives, but investors face risks from merger execution and economic cyclicality. The stock offers value with a consensus price target of $332.10, implying significant upside, supported by stable cash flows and a solid dividend track record.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

UNP

No sentiment data available yet.

VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Union Pacific Corporation

Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.

Read more on UNP →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →